Journal of Cancer Research and Therapeutics Close
 

Figure 7: (a) Deoxycholic acid and acid induce cyclooxygenase-2 promoter activity in esophageal cells. SKGT-4 cells were transfected with 5 μg of wild-type cyclooxygenase-2 promoter (−1432/+59, −327/+59) with intact nuclear factor-kappa B and activator protein-1 sites or the cyclooxygenase-2 plasmid lacking the response elements and exposed to deoxycholic acid 300 μM or pH 6.8 for 15 h. (b) Effect of nuclear factor-kappa B and activator protein-1 mutations of the cyclooxygenase-2 promoter plasmid on deoxycholic acid- and acid-induced cyclooxygenase-2 promoter activity. Deletion mutants of the cyclooxygenase-2 promoter plasmid were transfected into SKGT-4 cells and exposed to deoxycholic acid 300 μM or pH 6.8 for 15 h. KBM, represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the nuclear factor-kappa B site; CRM represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the CRE site and ILM, represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the C/EBP site. Luciferase activity from cells transfected with the constructs was normalized to luciferase activity from the cotransfected cells. Bars represent mean ± standard deviation

Figure 7: (a) Deoxycholic acid and acid induce cyclooxygenase-2 promoter activity in esophageal cells. SKGT-4 cells were transfected with 5 μg of wild-type cyclooxygenase-2 promoter (−1432/+59, −327/+59) with intact nuclear factor-kappa B and activator protein-1 sites or the cyclooxygenase-2 plasmid lacking the response elements and exposed to deoxycholic acid 300 μM or pH 6.8 for 15 h. (b) Effect of nuclear factor-kappa B and activator protein-1 mutations of the cyclooxygenase-2 promoter plasmid on deoxycholic acid- and acid-induced cyclooxygenase-2 promoter activity. Deletion mutants of the cyclooxygenase-2 promoter plasmid were transfected into SKGT-4 cells and exposed to deoxycholic acid 300 μM or pH 6.8 for 15 h. KBM, represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the nuclear factor-kappa B site; CRM represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the CRE site and ILM, represents the −327/+59 cyclooxygenase-2 plasmid, with a mutation in the C/EBP site. Luciferase activity from cells transfected with the constructs was normalized to luciferase activity from the cotransfected cells. Bars represent mean ± standard deviation